2. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161–167.
3. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278–1283.
4. Baumgarten G, Knuefermann P, Mann DL. Cytokines as emerging targets in the treatment of heart failure. Trends Cardiovasc Med 2000;10:216–223.
5. Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998;31:391–398.
6. Vizzardi E, D'Aloia A, Curnis A, Dei Cas L. Carbohydrate antigen 125: a new biomarker in heart failure. Cardiol Rev 2013;21:23–26.
7. Crespo Valades E, Malmierca Corral M. Elevated CA 125 in chronic liver disease with ascites. Gastroenterol Hepatol 2004;27:558.
8. Fernandez J, De Quiros B, Telenti M, et al. CA125 serum levels in tubercolosis patients. Int J Biol Markers 1995;10:180–181.
9. Lindgren J, Kuusela P, Hellstrom PE, Pettersson T, Klockars M. The ovarian cancer associated antigen CA 125 in patients with pleural effusions. Eur J Cancer Clin Oncol 1988;24:737–739.
10. Zuckerman E, Lanir A, Sabo E, et al. Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol 1999;94:1613–1618.
11. Mezger J, Wilmanns W, Lamerz R. Elevated serum CA 125 levels in patients with benign ascitic or pleural effusions. Tumour Biol 1988;9:47–52.
12. Kouris NT, Zacharos ID, Kontogianni DD, et al. The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 2005;7:199–203.
13. D'Aloia A, Faggiano P, Aurigemma G, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and shortterm prognosis. J Am Coll Cardiol 2003;41:1805–1811.
14. Varol E, Ozaydin M, Dogan A, Kosar F. Tumour marker levels in patients with chronic heart failure. Eur J Heart Fail 2005;7:840–843.
16. Kouris NT, Kontogianni DD, Papoulia EP, et al. Clinical and prognostic value of elevated CA125 levels in patients with congestive heart failure. Hellenic J Cardiol 2006;47:269–274.
17. Mansour IN, Napan S, Tarek Alahdab M, Stamos TD. Carbohydrate antigen 125 predicts long-term mortality in African American patients with acute decompensated heart failure. Congest Heart Fail 2010;16:15–20.
18. Kantar M, Levent E, Cetingul N, et al. Plasma natriuretic peptides levels and echocardiographic findings in late subclinical anthracycline toxicity. Pediatr Hematol Oncol 2008;25:723–733.
19. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, vonScheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001;38:1934–1941.
22. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157–172.
23. Hung CL, Hung TC, Liu CC, et al. Relation of carbohydrate antigen-125 to left atrial remodeling and its prognostic usefulness in patients with heart failure and preserved left ventricular ejection fraction in women. Am J Cardiol 2012;110:993–1000.
24. Karaca O, Guler GB, Guler E, et al. Serum carbohydrate antigen 125 levels in nonischemic dilated cardiomyopathy: a useful biomarker for prognosis and functional mitral regurgitation. Congest Heart Fail 2012;18:144–150.
25. De Gennaro L, Brunetti ND, Montrone D, De Rosa F, Cuculo A, Di Biase M. Inflammatory activation and carbohydrate antigen-125 levels in subjects with atrial fibrillation. Eur J Clin Invest 2012;42:371–375.
26. Antonini-Canterin F, Popescu BA, Popescu AC, et al. Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement. Int J Cardiol 2008;128:406–412.
27. Huang F, Chen J, Liu Y, Zhang K, Wang J, Huang H. New mechanism of elevated CA125 in heart failure: the mechanical stress and inflammatory stimuli initiate CA125 synthesis. Med Hypotheses 2012;79:381–383.
28. Ordu S, Ozhan H, Alemdar R, et al. Carbohydrate antigen-125 and N-terminal pro-brain natriuretic peptide levels: compared in heart-failure prognostication. Tex Heart Inst J 2012;39:30–35.
29. Bhalla V, Willis S, Maisel AS. B-type natriuretic peptide: the level and the drug. Partners in the diagnosis of congestive heart failure. Congest Heart Fail 2004;10(1 Suppl 1):3–27.
30. Atisha D, Bhalla MA, Morrison LK, et al. A prospective study in search of an optimal B-natriuretic peptide level screen patients for cardiac dysfunction. Am Heart J 2004;148:518–523.
31. Huang B, Shen J, Li L, Huang Y, Luo S. Effect of B-type natriuretic peptide level on long-term outcome in patients with end-stage heart failure. Am J Cardiol 2016;118:383–388.